Newsroom
Latest news, press coverage, and media appearances from our team
RNA Therapeutics, mRNA, Biotechnology, and Drug Development Trends
Before new therapies become headlines, biotech CEOs, founders, and scientists are already having very different conversations.
All Coverage
RNA Therapeutics, mRNA, AI, and Drug Development Explained
As Editor of Advancing RNA, Anna Rose Welch has become one of the most trusted voices to biotech leaders by bringing something science alone cannot: the ability to transform complexity into clarity. In this conversation with William Soliman, she shares the controversies, trends, and breakthroughs shaping the future of RNA therapeutics and drug development.
What Genentech and the FDA Teach Us About Responsible AI
Discover how Genentech is approaching the responsible adoption of AI in Medical Affairs and clinical development. Hear practical insights on balancing innovation with scientific rigor, human judgment, and governance to improve patient care and accelerate the future of medicine.
AI, Patent Cliffs, and the Future of Drug Development at BMS
From "Graveyard of Drug Development" to Opportunity: AI, Neuroscience, and Pharma's Next Chapter at BMS
William Soliman: LLY Retatrutide Raises the Bar in Weight Loss
Eli Lilly (LLY) leads in weight-loss drugs as retatrutide shows strong results. William Soliman highlights competition from Amgen (AMGN) and potential upside in Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), and Altimmune (ALT).
AI in Health Care: 8 Stocks to Buy Now
U.S. News Money examines how health care systems are investing in AI and spotlights eight companies at the forefront of the transition—from Alphabet and Amazon to Eli Lilly, Medtronic, Stryker, Boston Scientific, and Abbott—as AI helps clinicians diagnose conditions, monitor patients, and reduce administrative burden.
Global Pharma Giants Push Deeper Into AI-Driven Medicine, Precision Therapies
Forbes Middle East examines how Bayer and industry leaders like Roche, Novartis, and Pfizer are leveraging AI, precision oncology, and regenerative medicine to transform drug development. Includes insights from William Soliman on AI's role in accelerating clinical trials and the challenges of commercializing breakthrough therapies.
FDA Moves To Block Some Compounded GLP-1s - Here's What It Means For Online Prescriptions
Forbes examines the FDA's proposed move to limit some compounded GLP-1 medications and what that could mean for online prescribing. The piece includes perspective from William Soliman on how 503A and 503B compounding pathways affect telemedicine providers and patient access.
Want to Know What Lilly Saw Before Betting $2.8B on AI-Designed Drugs with Insilico?
Alex Zhavoronkov, CEO of Insilico Medicine, delivers a Masterclass in AI-Designed Drugs, exposes Pinocchio Deals, and kills Dinosaur AI Drug Discovery. See why, instead of looking for a needle in a haystack, generating a bunch of near-perfect needles earned them a $2.8B deal with Eli Lilly.
The Vaccine x Autism Myth, The Return of Measles and Other Preventable Diseases
Are we losing the battle against preventable diseases? Watch Dr. Kelly Moore, CEO, and Dr. LJ Tan, Chief Policy Officer from Immunize.org, weigh in on "what is fact and myth," along with Vaccine Committee Influencers, and what’s at risk for parents and children. Tune in to learn how they can protect themselves.
ABCNews Live Speaks with Will Soliman on Lilly’s $2.8B AI bet with Insilico
Eli Lilly just made a massive industry disruptor move with Insilico Medicine. Hear Will Soliman break down this major AI partnership in drug discovery and 2nd-gen obesity drugs.
Hidden Costs: PhRMA Shares Why Drug Prices Stay High and Who Profits Most
PhRMA's CMO, Dr. Mike Ybarra, exposes what he says are the hidden forces behind drug pricing, from intermediaries taking half of prescription spending to hospital markups under the 340B program, and warns how the Inflation Reduction Act’s “pill penalty” could threaten future drug innovation.
Unpacking FDA policy: Transparency, Industry, and AI's role
Go inside with former FDA Chief of Staff Julie Tierney, a 17-year veteran of the FDA. Julie shares insights on the biggest misconceptions about the FDA, the landmark legislation of the Cures Act, and the organization's commitment to evidence-based medicine. Rare opportunity to hear from being inside one of the largest and most impactful agencies in the world.
Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next, William Soliman, PhD, CEO, ACMA.
William Soliman, PhD, CEO of ACMA, examines the scaling challenges and breakthroughs in oligonucleotide therapeutics — from manufacturing bottlenecks to the innovations reshaping RNA-based drug development.
Dr. Daniel Quirk Shares the Blueprint That’s Got Biogen Focused, and Why That’s Good for Patients
Daniel Quirk brings 20 years of bedside experience to his role as Biogen’s CMO, with a focus on scaling patient impact beyond the exam room. That shows up in a pipeline built to deliver with 10 advancing assets, disciplined use of AI only where it improves outcomes, and Medical Affairs treated as an extension of patient care, turning complex science into practice-informing insight
Rob Long's Story: From NFL Prospect to Rare Cancer Fighter to Saving Lives
Former All-American punter Rob Long, Executive Director, Uplifting Athletes, shares his powerful story with Will Soliman on overcoming a devastating, rare brain cancer diagnosis with no cure during his senior year at Syracuse University, and how his fight led him to a new mission.
.svg)
Healthcare Infrastructure and Primary Care Policy: A Strategic Analysis with AAFP President Dr. Sarah Nosal
Dr. Sarah Nosal, President of the American Academy of Family Physicians (AAFP), examines the systemic funding crisis in U.S. primary care and the administrative impact of prior authorizations. This discussion highlights the clinical necessity of evidence-based standards amidst evolving vaccine guidelines and the rise of AI-driven claim denials.
ACMA's Next-Generation Artificial Intelligence Board Certification for Medical Science Liaisons
Oradell, NJ — November 13, 2025 — The Accreditation Council for Medical Affairs (ACMA) has launched a new AI-integrated Board Certified Medical Affairs Specialist (BCMAS®) program, redefining Medical Affairs training by teaching AI literacy and application to Medical Science Liaisons (MSLs) and field medical professionals.
American Medical Association (AMA), President Dr.Bobby Mukkamala faced a brain tumor - and a broken prior authorization system. Hear his incredible fight for survival and reform
Prior Auth Impacts Everyone: Hear President Dr. Bobby Mukkamala, President, American Medical Association, tell his story of facing a brain tumor and a broken prior authorization system. Hear his incredible fight for survival and reform.
The Accreditation Council for Medical Affairs Announces Launch of ACMAi at Fierce Pharma Week 2025
The Accreditation Council for Medical Affairs (ACMA) has unveiled ACMAi, a groundbreaking AI-powered learning solution designed to transform professional development in the pharmaceutical and life sciences industries. Officially launched at Fierce Pharma Week 2025, ACMAi delivers adaptive, accredited, and impactful training for medical affairs, market access, and commercial teams worldwide.
Pharma CEOs Facing Favored Nation Pricing Challenges: Dr. Soliman Explains the Impact
William Soliman appears on Fox News to discuss the implications of the White House Executive Order on drug pricing. At the ACMA, we're focused on preparing professionals to navigate the complex intersection of policy, science, and access.
Chasing Cures: Dr. David Fajgenbaum - Beating Last Rites and Redefining Rare Disease Research
Dr. David Fajgenbaum, physician-scientist, Times Health 100 and TED speaker, and bestselling author of Chasing My Cure, joins Dr. William Soliman to discuss how he turned a life-threatening diagnosis into a global movement to accelerate rare disease research.
.jpg&w=3840&q=100)
William Soliman on the impact of the "Big Beautiful Bill" in Pharma
William Soliman joins Armstrong Williams from The Armstrong Williams Show to discuss President Trump's "Big Beautiful Bill," its potential impact on pharma, healthcare, and more.
Legacy in Action: Sonja Allen's Inspirational Story to Change a Broken Healthcare System
Sonja Allen continues the legacy of her late husband, Marshall Allen, Pulitzer Prize finalist and bestselling author of Never Pay the First Bill. In this inspiring interview, she shares how she turned grief into purpose, empowering patients and launching an AI tool to fight unfair medical bills.
The Administration's Biggest Impacts on Pharma
Dr. William Soliman speaks with Pharmaceutical Executive about how shifting regulations, rising tariffs, and faster drug approvals are pressuring pharma companies to rethink compliance, field readiness, and the role of medical affairs.
Health Insurers address prior authorization issues
Learn about an agreement with the health insurance industry to streamline the prior authorization process and what it means for patients.
The broken Prior Authorization process is hurting Americans
The broken Prior Authorization process is hurting Americans. North Carolina Rep. Tim Reeder, MD, discusses his Care First Act House Bill 434 and how a psychiatrist second-guessed a surgeon's handling a potentially life-threatening cancerous pelvic tumor - recommending birth control instead.
Elizabeth Vargas, NewsNation talks with William Soliman on the national risks of tariffs on patient medicines
Watch Elizabeth Vargas from NewsNation interview with William Soliman, CEO & Founder, of ACMA. A powerful conversation about the national security risk issues that deserve far more national attention — the impact of Trump-era tariffs on the pharma industry and how these policies are affecting Americans access to critical medications.
Biosimilars Require Standardization of Knowledge in the Field
Pharmacy Times sat down with a panel of experts to discuss progress toward standardization of knowledge in the field of biosimilars, with panelists including William Soliman, PhD, founder and CEO of the Accreditation Council for Medical Affairs (ACMA); Jeff Baldetti, MBA, BCBBS, vice president of product and marketing at HealthPlan Data Solutions; and Fran Gregory, PharmD, vice president of emerging therapies and biosimilars at Cardinal Health.
The Crucial Role of Medical Affairs in Bridging the Educational Gap Among Healthcare Professionals in Biosimilars
Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap
Impact of Humira biosimilars on the US market
Clarivate webinar discussing how the entry of Humira (adalimumab) biosimilars into the U.S. market following Humira’s patent expiry could affect competition, pricing, and the broader healthcare landscape for biologics and biosimilar developers.
Nurses looking to build their careers in the pharmaceutical industry now have a path forward
Nurses now have a clear pathway into pharmaceutical careers through the launch of the Certified Nurse Medical Affairs Professional (CNMAP™) Program, the first accredited certification helping them apply clinical skills in the biopharmaceutical industry.
Pharma, PBMs Blame Each Other Under Intense Scrutiny from Sanders' Health Committee
CEOs from Eli Lilly, Sanofi, and Novo Nordisk, along with executives from three pharmacy benefit managers (PBMs), appeared before the Senate Committee on Health, Education, Labor and Pension (HELP) to address insulin price reform. These companies control 90% of the global insulin market. The Inflation Reduction Act (IRA) has forced them to cap insulin copays at $35 per month and cap insulin expenses for seniors at $2,000 per year through Medicare. The high cost of insulin was attributed to both PBMs and pharmaceutical companies, with senators criticizing the lack of transparency in PBM operations. Dr. William Soliman, founder and CEO of the Accreditation Council for Medical Affairs, highlighted the need for PBM reform and Congressional action to achieve results. The urgency for revolutionary changes in the prescription drug system was emphasized.
After working at Merck during the Vioxx scandal, this former sales rep is on a mission to fix the system
William Soliman, CEO and founder of the Accreditation Council for Medical Affairs (ACMA), is working to establish competency standards and prevent conflicts between medical affairs departments and marketing in the pharmaceutical industry. ACMA certifies and accredits medical affairs and medical science liaisons, and Soliman aims to create uniform standards for the profession to avoid future pharmaceutical scandals. He emphasizes the importance of ethics and appropriate reporting structures within medical affairs, separating it from commercial influences
Interview with William Soliman on Medical Science Liaisons
In this episode, Dr. Soliman, CEO of the Accreditation Council for Medical Affairs (ACMA), about his background, the influence of his father, and the role of the pharmaceutical industry. Growing up in Jersey City, Will was encouraged by his parents to pursue a career in STEM, leading him to major in biochemistry in college. He discusses the impact of 9/11 on immigration policies and scientific output, as well as his early career as a pharmaceutical sales rep before transitioning to a medical science liaison role.
ACMA partners with the Pharmaceutical Research & Manufacturers Association in the Gulf (PhRMAG) to streamline Prior Authorization Challenges in the UAE
The Accreditation Council for Medical Affairs (ACMA) and The Pharmaceutical Research and Manufacturers Association in the Gulf (PhRMAG) have partnered to establish an endowment aimed at enhancing the skills and credentials of healthcare professionals in the Middle East Gulf Region. This collaboration, initiated by Husam Al Majali of Merck and Jamie Phares of Janssen, will offer the globally accredited Prior Authorization Certified Specialist (PACS) credential to major healthcare systems in the area. PhRMAG, representing leading biopharmaceutical research companies in the Gulf, focuses on advancing medical research and patient care, while ACMA is renowned for setting industry standards and providing accredited certifications for both the pharmaceutical industry and healthcare providers.
Dr. William Soliman highlighted in Forbes on the racial inequality gap in healthcare
Oprah Winfrey is releasing a new documentary called the Color of Care which highlights racial equality gaps in healthcare especially highlighted during the Covid19 pandemic. See Dr Soliman quoted and featured in this article published by Forbes regarding the importance of the work we are doing at the Accreditation Council for Medical Affairs (ACMA) around the establishment of standards for MSL and Medical affairs professionals as they play a very important role in educating the healthcare provider community.
Moment of Xen Interview on iHeart Radio with Xen Sams
Check out our founder and CEO Dr. William Soliman /Accreditation Council for Medical Affairs (ACMA) this weekend on iHeart Radio's A Moment of Xen w/t Xen Sams in My Healthy Minutes segment sponsored by Revere Securities where he'll discuss the ongoing opioid crisis in America, how psychedelics and cannabis are potentially used to treat addictions, mental and neurological disorders, and the priceless education the Accreditation Council for Medical Affairs (ACMA) is providing the pharmaceutical industry.
Rebuild US Healthcare at Reuters 2022
During the Reuters Event, there will be an industry-focused conversation on key topics leading pharma in 2022. This event is held to provide content that is driven by experts in their fields: marketing, commercial, data & analytics, patient engagement, patient advocacy, medical affairs, market access, RWE and clinical. As a Gold Sponsor and media partner, the event will offer continuing medical education/continuing education (CME/CE) credits to attendees.
Discussing the Merck and J&J Merger
The ACMA frequently provides expertise about the pharmaceutical industry. In this video, Founder & CEO of the ACMA, Dr. William Soliman, speaks on Al Jazeera about the unprecedented cooperation within the pharmaceutical industry to expedite the development of the COVID-19 vaccine.
US Government Deal with Gilead Sciences
The ACMA's Founder & CEO Dr. William Soliman speaks on Al Jazeera to discuss the US Government's deal with Gilead Sciences to secure the COVID-19 vaccine. Is this a sign for things to come? Will patients in developing countries have adequate access to COVID-19 vaccines?
Discussing the $260MM Opioid Settlement
The ACMA's Founder & CEO Dr. William Soliman on Al Jazeera Newshour discusses how the $260 million opioid settlement is a wakeup call to Pharma companies. Dr. Soliman indicates that pharma companies need to overhaul their "old ways" of training and preparing employees, who are responsible for educating doctors and healthcare providers.
Board Certification for Medical Science Liaisons: Implications for the Pharmaceutical Industry
An in-depth look at how board certification for Medical Science Liaisons is raising professional standards across the pharmaceutical industry and shaping the future of medical affairs.
The Foundations of Pharmaceutical Industry Compliance
Exploring the foundational principles of pharmaceutical industry compliance and the role of standardized training in maintaining ethical practices across medical affairs teams.
Expert Opinion Roundup: New Insulin and Biosimilar Regulation
A roundup of expert opinions on the latest insulin and biosimilar regulations, examining how new policies are reshaping access, competition, and patient care in the biologics market.
Navigating Medication Safety During and After the COVID-19 Pandemic
Strategies for navigating medication safety during and after the COVID-19 pandemic, addressing the challenges healthcare professionals faced in maintaining standards of care amid unprecedented disruption.
ACMA Launches Medication Safety Service to Mitigate New Product Risks
The Accreditation Council for Medical Affairs launches a new medication safety service designed to help pharmaceutical companies identify and mitigate risks associated with new product launches.
ACMA Announces New Investment and Expansion in the Asian Life Sciences Market
ACMA announces a strategic investment and expansion into the Asian life sciences market, bringing accredited medical affairs training and certification programs to a growing global audience.
Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive Review
A comprehensive review of Medical Affairs and Medical Science Liaison board certification, examining its impact on professional standards, career development, and industry-wide competency.
ACMA Launches First CRM Designed Exclusively for Medical Affairs/MSLs in the Life Sciences Industry
ACMA launches the first CRM platform designed exclusively for Medical Affairs and MSLs in the life sciences industry, purpose-built to meet the unique needs of field medical teams.
Consider Professional Development During COVID-19
Why healthcare and life sciences professionals should consider continuing professional development during the COVID-19 pandemic — and how accredited programs support career growth even in challenging times.
Accreditation Council for Medical Affairs launches accredited Prior Authorization Certified Specialist program
The Accreditation Council for Medical Affairs launches the Prior Authorization Certified Specialist (PACS) program, the first accredited certification designed to standardize expertise in the prior authorization process.
COVID-19 and Medical Affairs
How the COVID-19 pandemic reshaped the role of Medical Affairs in the pharmaceutical industry, from rapid response to long-term strategic adaptation in a changing healthcare landscape.